Sanofi

This trial is testing whether an experimental mRNA vaccine can safely reduce moderate-to-severe acne in adolescents aged 12 to 17. Participants receive either the vaccine at different dose levels or a placebo, and researchers monitor safety and changes in facial acne lesions. The…

This study is checking the safety of a high-dose flu vaccine called Efluelda in adults aged 65 and older in South Korea. About 670 participants will receive one shot and be monitored for side effects for about a month. The goal is to see how often reactions like injection site pa…

This study is checking the safety of a high-dose flu vaccine called Efluelda Tetra in adults aged 65 and older in South Korea. About 670 participants will receive one dose and be monitored for side effects for about a month. The goal is to see how often reactions like injection s…

This phase 3 trial is testing whether the oral drug belumosudil works better than the best available therapy for people aged 12 and older with chronic graft-versus-host disease (cGVHD) that has not improved or has returned after 2 to 5 prior treatments. Participants are randomly …

Researchers are testing different doses of duvakitug, an injected drug, against placebo in adults with moderate to severe hidradenitis suppurativa. The trial enrolls about 156 people who have painful lumps and tunnels in at least two skin areas. Participants receive either duvaki…

This trial compares a liquid (oral suspension) form of the drug belumosudil with the standard tablet in healthy adult men. The goal is to see if the liquid version is absorbed by the body in the same way, which could offer a more convenient option for people with chronic graft-ve…

This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants take the drug for up to 24 weeks, and doctors monitor for side effects an…